FEATURED

Advertisement
Sign Up for Newsletter
Your Support

NEWS

CONFERENCE COVERAGE

Precision Radiation Therapy in Inoperable Early-Stage Lung Cancer: What SWOG/NRG S1914 Tells Us

Peter Hofland -

Zipalertinib Plus Chemotherapy Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Mutated NSCLC

Peter Hofland -

DESTINY-Lung04 Shows a First-Line PFS Benefit With Trastuzumab Deruxtecan in HER2-Mutant NSCLC, While Overall...

Danielle Garcia -

Zidesamtinib Moves Toward the Front Line – New ARROS-1 Data in Treatment-Naive ROS1-Positive Lung...

Peter Hofland -

Risvutatug Rezetecan Shows a Survival Advantage Over Topotecan in Relapsed Small Cell Lung Cancer

Peter Hofland -

Response to Neoadjuvant Immunochemotherapy May Guide Surgical De-escalation in HPV-Negative Head and Neck Cancer

Danielle Garcia -

FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC, as Trial Data...

Peter Hofland -

Genomic Tests Guide Chemotherapy Decisions in Advanced Prostate and Breast Cancer: Landmark Evidence from...

Peter Hofland -

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab...

Peter Hofland -

Asciminib Maintains Superior Efficacy and Favorable Safety Profile in Newly Diagnosed Chronic Myeloid Leukemia

Peter Hofland -

From Data to Delivery: How Real-World Evidence Is Transforming Oncology Care

Jessica K. Paulus, ScD -

ASCO 2026: Phase 1 Study of Denileukin Diftitox Plus Pembrolizumab in Recurrent or Refractory...

Peter Hofland -
Advertisement
Your Support
Sign Up for Newsletter

EDITORIAL

ERIC ROSENTHAL REPORTS

EXPERT INTERVIEWS

spot_img
spot_img
spot_img
spot_img
spot_img
spot_img